Iqvia Holdings Inc (IQV) Shares Bought by GWM Advisors LLC

GWM Advisors LLC grew its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 31.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,951 shares of the medical research company’s stock after buying an additional 1,195 shares during the period. GWM Advisors LLC’s holdings in Iqvia were worth $642,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of IQV. First Trust Advisors LP bought a new position in shares of Iqvia during the 2nd quarter worth approximately $99,127,000. Laurion Capital Management LP boosted its holdings in shares of Iqvia by 188.1% during the 2nd quarter. Laurion Capital Management LP now owns 378,318 shares of the medical research company’s stock worth $37,764,000 after buying an additional 807,697 shares in the last quarter. USS Investment Management Ltd bought a new position in shares of Iqvia during the 3rd quarter worth approximately $86,508,000. BlackRock Inc. boosted its holdings in shares of Iqvia by 5.7% during the 2nd quarter. BlackRock Inc. now owns 10,170,048 shares of the medical research company’s stock worth $1,015,173,000 after buying an additional 546,878 shares in the last quarter. Finally, Atalanta Sosnoff Capital LLC bought a new position in shares of Iqvia during the 3rd quarter worth approximately $51,970,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Shares of IQV opened at $121.71 on Friday. Iqvia Holdings Inc has a 12-month low of $91.57 and a 12-month high of $135.48. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $24.87 billion, a P/E ratio of 27.92, a PEG ratio of 1.76 and a beta of 0.80.

Iqvia (NYSE:IQV) last issued its earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The company had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, sell-side analysts forecast that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

In other Iqvia news, Director John G. Danhakl sold 370,470 shares of the firm’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total transaction of $46,245,770.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John G. Danhakl sold 221,900 shares of the firm’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $126.63, for a total value of $28,099,197.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 601,586 shares of company stock worth $75,510,422. Company insiders own 6.00% of the company’s stock.

A number of equities analysts have issued reports on the company. Royal Bank of Canada restated a “$110.25” rating and set a $128.00 price target on shares of Iqvia in a report on Thursday, July 19th. Argus set a $136.00 price target on Iqvia and gave the stock a “buy” rating in a report on Thursday, August 23rd. Piper Jaffray Companies restated a “hold” rating and set a $97.00 price target on shares of Iqvia in a report on Wednesday, July 25th. Barclays restated an “overweight” rating and set a $130.00 price target (up from $120.00) on shares of Iqvia in a report on Wednesday, July 25th. Finally, Bank of America upgraded Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 price target on the stock in a report on Wednesday, July 25th. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $131.67.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply